{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:20:25Z","timestamp":1762507225314,"version":"3.37.3"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.atherosclerosis.2017.09.029","type":"journal-article","created":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T12:47:01Z","timestamp":1506689221000},"page":"81-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Dronedarone exerts anticoagulant and antiplatelet effects independently of its antiarrhythmic actions"],"prefix":"10.1016","volume":"266","author":[{"given":"M. Urooj","family":"Zafar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos G.","family":"Santos-Gallego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan L.","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan J.","family":"Badimon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"doi-asserted-by":"crossref","unstructured":"Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449\u20131457.","key":"10.1016\/j.atherosclerosis.2017.09.029_bib1","DOI":"10.1001\/archinte.1994.00420130036007"},{"key":"10.1016\/j.atherosclerosis.2017.09.029_bib2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the framingham study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke; A J. Cereb. Circulation"},{"key":"10.1016\/j.atherosclerosis.2017.09.029_bib3","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1001\/archinte.165.10.1185","article-title":"Occurrence and characteristics of stroke events in the atrial fibrillation follow-up investigation of sinus rhythm management (AFFIRM) study","volume":"165","author":"Sherman","year":"2005","journal-title":"Arch. Intern Med."},{"issue":"527","key":"10.1016\/j.atherosclerosis.2017.09.029_bib4","first-page":"e1","article-title":"Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study","volume":"156","author":"Davy","year":"2008","journal-title":"Am. Heart J."},{"key":"10.1016\/j.atherosclerosis.2017.09.029_bib5","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1056\/NEJMoa0803778","article-title":"Effect of dronedarone on cardiovascular events in atrial fibrillation","volume":"360","author":"Hohnloser","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2017.09.029_bib6","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1161\/CIRCULATIONAHA.109.858027","article-title":"Dronedarone","volume":"120","author":"Patel","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2017.09.029_bib7","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa054686","article-title":"Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter","volume":"357","author":"Singh","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2017.09.029_bib8","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0195-668X(03)00321-X","article-title":"Dronedarone for prevention of atrial fibrillation: a dose-ranging study","volume":"24","author":"Touboul","year":"2003","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2017.09.029_bib9","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1161\/CIRCULATIONAHA.109.875252","volume":"120","author":"Connolly","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2017.09.029_bib10","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa021375","article-title":"A\u00a0comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation","volume":"347","author":"Van Gelder","year":"2002","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2017.09.029_bib11","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1056\/NEJMoa021328","article-title":"A\u00a0comparison of rate control and rhythm control in patients with atrial fibrillation","volume":"347","author":"Wyse","year":"2002","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2017.09.029_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2017.03.023","article-title":"Platelet reactivity and mean platelet volume as risk markers of thrombogenesis in atrial fibrillation","volume":"235","author":"Makowski","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2017.09.029_bib13","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.thromres.2015.02.022","article-title":"Detection of elevated INR by thromboelastometry and thromboelastography in warfarin treated patients and healthy controls","volume":"135","author":"Schmidt","year":"2015","journal-title":"Thromb. Res."},{"key":"10.1016\/j.atherosclerosis.2017.09.029_bib14","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s11239-016-1399-3","article-title":"Effects of non-vitamin K antagonist oral anticoagulants on fibrin clot and whole blood clot formation, integrity and thrombolysis in patients with atrial fibrillation","volume":"42","author":"Lau","year":"2016","journal-title":"J.\u00a0Thromb. Thrombolysis"},{"year":"2006","author":"Agency","series-title":"Withdrawal Public Assessment Report of the Marketing Authorisation Application for Multaq","key":"10.1016\/j.atherosclerosis.2017.09.029_bib15"},{"key":"10.1016\/j.atherosclerosis.2017.09.029_bib16","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s00395-012-0302-4","article-title":"Dronedarone reduces arterial thrombus formation","volume":"107","author":"Breitenstein","year":"2012","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2017.09.029_bib17","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/europace\/eut293","article-title":"Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial","volume":"16","author":"Pisters","year":"2014","journal-title":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : J. Work. groups cardiac pacing, Arrhythm. cardiac Cell. Electrophysiol. Eur. Soc. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2017.09.029_bib18","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1056\/NEJMoa1109867","article-title":"Dronedarone in high-risk permanent atrial fibrillation","volume":"365","author":"Connolly","year":"2011","journal-title":"N.\u00a0Engl. J. Med."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915017313151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915017313151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T21:58:35Z","timestamp":1617487115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915017313151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":18,"alternative-id":["S0021915017313151"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.09.029","relation":{},"ISSN":["0021-9150"],"issn-type":[{"type":"print","value":"0021-9150"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dronedarone exerts anticoagulant and antiplatelet effects independently of its antiarrhythmic actions","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.09.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}